Aptose Biosciences Inc. (0UI8.L)

2.6000 -4.2700 (-62.15%) At close: 03:52PM BST

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828
https://www.aptose.com

Sector(s): 
Industry: 
Full-time employees: 35

Key executives

Name	Title	Pay	Exercised	Year born
Dr. William G. Rice Ph.D.	Chairman, President, CEO & Chief Accounting Officer	897.03k	N/A	1959
Mr. Fletcher Payne	Senior VP, CFO, Chief Business Officer & Secretary	647.97k	N/A	1963
Dr. Rafael Bejar M.D., Ph.D.	Senior VP & Chief Medical Officer	687.88k	N/A	1973
Dr. Marc Wiles Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Brooks Ensign M.B.A.	VP & Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Corporate governance

Aptose Biosciences Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.